
Marisa Battistella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2134370/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk of Upper Gastrointestinal Hemorrhage in Warfarin Users Treated With Nonselective NSAIDs or COX-2 Inhibitors. Archives of Internal Medicine, 2005, 165, 189.	3.8	129
2	Canadian Society of Nephrology Commentary on the KDIGO Clinical Practice Guideline for CKD Evaluation and Management. American Journal of Kidney Diseases, 2015, 65, 177-205.	1.9	98
3	Systematic Review of the Risk of Adverse Outcomes Associated with Vascular Endothelial Growth Factor Inhibitors for the Treatment of Cancer. PLoS ONE, 2014, 9, e101145.	2.5	68
4	A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrology Dialysis Transplantation, 2019, 34, 265-277.	0.7	64
5	Targeted Deprescribing in an Outpatient Hemodialysis Unit: AÂQuality Improvement Study to Decrease Polypharmacy. American Journal of Kidney Diseases, 2017, 70, 611-618.	1.9	56
6	Long-term Follow-up of the Hemodialysis Infection Prevention With Polysporin Ointment (HIPPO) Study: A Quality Improvement Report. American Journal of Kidney Diseases, 2011, 57, 432-441.	1.9	40
7	Implementation of a Near-Peer Teaching Model in Pharmacy Education: Experiences and Challenges. Canadian Journal of Hospital Pharmacy, 2012, 65, 394-8.	0.1	34
8	Evaluating time in therapeutic range for hemodialysis patients taking warfarin. Clinical Nephrology, 2015, 83 (2015), 80-85.	0.7	31
9	Measuring pain in patients undergoing hemodialysis: a review of pain assessment tools. CKJ: Clinical Kidney Journal, 2014, 7, 367-372.	2.9	25
10	Direct Oral Anticoagulant Use in Chronic Kidney Disease and Dialysis Patients With Venous Thromboembolism: A Systematic Review of Thrombosis and Bleeding Outcomes. Annals of Pharmacotherapy, 2021, 55, 711-722.	1.9	25
11	A Province-wide, Cross-sectional Study of Demographics and Medication Use of Patients in Hemodialysis Units Across Ontario. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811876083.	1.1	21
12	Fomepizole as an Antidote for Ethylene Glycol Poisoning. Annals of Pharmacotherapy, 2002, 36, 1085-1089.	1.9	19
13	Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review. Annals of Pharmacotherapy, 2021, 55, 509-529.	1.9	18
14	Vascular accessâ€related infection in nocturnal home hemodialysis. Hemodialysis International, 2014, 18, 481-487.	0.9	17
15	Addressing Polypharmacy in Outpatient Dialysis Units. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 144-146.	4.5	17
16	Canadian Society of Nephrology Commentary on the Kidney Disease Improving Global Outcomes 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812094427.	1.1	16
17	Potentially inappropriate prescribing in older adults with advanced chronic kidney disease. PLoS ONE, 2020, 15, e0237868.	2.5	14
18	A FORMAL MEDICATION RECONCILIATION PROGRAMME IN A HAEMODIALYSIS UNIT CAN IDENTIFY MEDICATION DISCREPANCIES AND POTENTIALLY PREVENT ADVERSE DRUG EVENTS. Journal of Renal Care, 2015, 41, 104-109.	1.2	11

#	Article	IF	CITATIONS
19	Domperidone-Associated Sudden Cardiac Death in the General Population and Implications for Use in Patients Undergoing Hemodialysis: A Literature Review. Canadian Journal of Hospital Pharmacy, 2014, 67, 441-6.	0.1	10
20	Warfarin Use in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review of Stroke and Bleeding Outcomes. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811773553.	1.1	10
21	Conversion from Epoetin Alfa to Darbepoetin Alfa: Effects on Patients' Hemoglobin and Costs to Canadian Dialysis Centres. Canadian Journal of Hospital Pharmacy, 2012, 65, 443-9.	0.1	9
22	Development and Validation of Nine Deprescribing Algorithms for Patients on Hemodialysis to Decrease Polypharmacy. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812096867.	1.1	9
23	Development, validation, and implementation of a medication adherence survey to seek a better understanding of the hemodialysis patient. Clinical Nephrology, 2016, 85 (2016), 12-22.	0.7	9
24	Patterns of cardioprotective medication prescription in incident hemodialysis patients. International Urology and Nephrology, 2009, 41, 1021-1027.	1.4	8
25	Stability of Trisodium Citrate and Gentamicin Solution for Catheter Locks after Storage in Plastic Syringes at Room Temperature. Canadian Journal of Hospital Pharmacy, 2010, 63, 304-11.	0.1	8
26	Medications Used Routinely in Primary Care to be Dose-Adjusted or Avoided in People With Chronic Kidney Disease: Results of a Modified Delphi Study. Annals of Pharmacotherapy, 2020, 54, 625-632.	1.9	8
27	Antibiotic lock: In vitro stability of vancomycin and four percent sodium citrate stored in dialysis catheters at 37ŰC. Hemodialysis International, 2009, 13, 322-328.	0.9	7
28	Use of Fondaparinux for Circuit Patency in Hemodialysis Patients. American Journal of Kidney Diseases, 2013, 61, 525-526.	1.9	7
29	Cultivating Innovative Pragmatic Cluster-Randomized Registry Trials Embedded in Hemodialysis Care: Workshop Proceedings From 2018. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811989439.	1.1	7
30	Nephrology practice and research network opinion paper: Pharmacists' perspectives on the Advancing American Kidney Health initiative. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 1355-1368.	1.0	7
31	An Observational Case Study of Near-peer Teaching in Medical and Pharmacy Experiential Training. American Journal of Pharmaceutical Education, 2016, 80, 114.	2.1	7
32	Clinical Outcomes of Failing to Dose-Reduce Cephalosporin Antibiotics in Older Adults with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 197-205.	4.5	6
33	Development and Validation of a Uremic Pruritus Treatment Algorithm and Patient Information Toolkit in Patients With Chronic Kidney Disease and End Stage Kidney Disease. Journal of Pain and Symptom Management, 2020, 59, 279-292.e5.	1.2	6
34	Retinoic acid syndrome after one dose of all-transretinoic acid. Journal of Oncology Pharmacy Practice, 2004, 10, 149-154.	0.9	5
35	Antibiotic lock: In vitro stability of gentamicin and sodium citrate stored in dialysis catheters at 37â€f°C. Hemodialysis International, 2010, 14, 322-326.	0.9	5
36	Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia. International Journal of Nephrology and Renovascular Disease, 2021, Volume 14, 301-311.	1.8	5

MARISA BATTISTELLA

#	Article	IF	CITATIONS
37	Pharmacy Practice Standards for Outpatient Nephrology Settings. Kidney Medicine, 2022, 4, 100509.	2.0	5
38	Cost Savings Using a Protocol Approach to Manage Anemia in a Hemodialysis Unit. American Journal of Nephrology, 2014, 39, 509-514.	3.1	4
39	Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin. Kidney International Reports, 2020, 5, 159-164.	0.8	4
40	Principles of Drug Dosing in Sustained Low Efficiency Dialysis (SLED) and Review of Antimicrobial Dosing Literature. Pharmacy (Basel, Switzerland), 2020, 8, 33.	1.6	4
41	Optimized Dosing of Cefazolin in Patients Treated With Nocturnal Home Hemodialysis. American Journal of Kidney Diseases, 2014, 64, 479-480.	1.9	3
42	Development and validation of a constipation treatment toolkit for patients on hemodialysis. Hemodialysis International, 2021, , .	0.9	3
43	How Can Erythropoeitin‣timulating Agent Use be Reduced in Chronic Dialysis Patients?. Seminars in Dialysis, 2013, 26, 537-540.	1.3	1
44	Lower opioid and higher adjuvant analgesic use in patients on haemodialysis: A single entre crossâ€sectional study. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1295-1300.	1.5	1
45	A retrospective study of antithrombotic therapy use in an outpatient haemodialysis unit. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1387-1394.	1.5	1
46	Understanding pruritis in dialysis patients. CANNT Journal = Journal ACITN, 2013, 23, 19-23; quiz 24-5.	0.0	1
47	Pain assessment and management in hemodialysis patients. CANNT Journal = Journal ACITN, 2013, 23, 29-32; quiz 33-4.	0.0	1
48	Clinical remission as measured by a decrease in intact parathyroid hormone levels after administration of cinacalcet in patients with severe hyperparathyroidism. Nephrology Dialysis Transplantation, 2007, 23, 773-774.	0.7	0
49	Pharmacokinetic Study of Cefazolin in Short Daily Hemodialysis. Annals of Pharmacotherapy, 2019, 53, 348-356.	1.9	0
50	Management of Diabetes 100 Years After the Discovery of Insulin: Nuances for the Kidney. Kidney Medicine, 2021, 3, 159-161.	2.0	0
51	Patterns of Antimicrobial Use in an Outpatient Hemodialysis Unit. Canadian Journal of Hospital Pharmacy, 2022, 75, 15-20.	0.1	0
52	Potentially inappropriate prescribing in older adults with advanced chronic kidney disease. , 2020, 15, e0237868.		0
53	Potentially inappropriate prescribing in older adults with advanced chronic kidney disease. , 2020, 15, e0237868.		0
54	Potentially inappropriate prescribing in older adults with advanced chronic kidney disease. , 2020, 15, e0237868.		0

#	Article	IF	CITATIONS
55	Potentially inappropriate prescribing in older adults with advanced chronic kidney disease. , 2020, 15, e0237868.		0